Publications by authors named "Ulrich Germing"

100Publications

Wilm's Tumor 1-guided preemptive treatment with hypomethylating agents for molecular relapse of AML and MDS after allogeneic transplantation.

Bone Marrow Transplant 2020 Sep 2. Epub 2020 Sep 2.

Department of Hematology, Oncology and Clinical Immunology, University Hospital Duesseldorf, Medical Faculty, Heinrich Heine-University, Duesseldorf, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-020-01039-2DOI Listing
September 2020

Prediction of Response and Survival Following Treatment with Azacitidine for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes after Allogeneic Hematopoietic Stem Cell Transplantation.

Cancers (Basel) 2020 Aug 12;12(8). Epub 2020 Aug 12.

Department of Hematology, Oncology and Clinical Immunology, University Hospital Duesseldorf, Medical Faculty, Heinrich Heine-University, Duesseldorf, Moorenstr. 5, 40225 Duesseldorf, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers12082255DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7464210PMC
August 2020

Falciparum malaria-induced secondary hemophagocytic lymphohistiocytosis successfully treated with ruxolitinib.

Int J Infect Dis 2020 Aug 7. Epub 2020 Aug 7.

Department of Gastroenterology, Hepatology and Infectious Diseases, Duesseldorf University Hospital, Heinrich Heine University, Duesseldorf, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijid.2020.07.062DOI Listing
August 2020

Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes.

Nat Med 2020 Aug 3. Epub 2020 Aug 3.

Computational Oncology Service, Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41591-020-1008-zDOI Listing
August 2020

Improving the accuracy of prognostication in chronic myelomonocytic leukemia.

Expert Rev Anticancer Ther 2020 Aug 6;20(8):703-714. Epub 2020 Aug 6.

Department of Hematology, Oncology and Clinical Immunology, Medical Faculty, University of Duesseldorf , Duesseldorf, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737140.2020.1796644DOI Listing
August 2020

Prognostic value of indoleamine 2,3 dioxygenase in patients with higher-risk myelodysplastic syndromes treated with azacytidine.

Br J Haematol 2020 Aug 29;190(3):361-370. Epub 2020 Apr 29.

Institute of Pathology, Ludwig-Maximilians-Universität München, Munich, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.16652DOI Listing
August 2020

Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes.

N Engl J Med 2020 01;382(2):140-151

From Service d'Hématologie Séniors, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris and Université Paris 7, Paris (P.F., L.A.), Service des Maladies du Sang, Hôpital Huriez, Centre Hospitalier Universitaire (CHU) de Lille, Lille (B.Q.), the Department of Internal Medicine, CHU Toulouse, Institut Universitaire du Cancer de Toulouse, Toulouse (O.B.-R.), and Université Cote d'Azur, Département d'Hématologie Clinique, CHU Nice, Nice (T.C.) - all in France; Medical Clinic and Policlinic 1, Hematology and Cellular Therapy, Leipzig University Hospital, Leipzig (U.P.), Klinik für Hämatologie, Onkologie, and Klinische Immunologie, Universitätsklinik Düsseldorf, Düsseldorf (U.G.), and Klinik und Poliklinik für Innere Medizin III, Technische Universität München, Munich (K.S.G.) - all in Germany; the Department of Haemato-Oncology, King's College London, London (G.J.M.), Radcliffe Department of Medicine, University of Oxford, John Radcliffe Hospital, Oxford (P.V.), and the Department of Haematology, Leeds Teaching Hospitals NHS Trust, Leeds (D.B.) - all in the United Kingdom; the Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston (G.G.-M.); Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto (R.B.); MDS Unit, Azienda Ospedaliero Universitaria Careggi, University of Florence, Florence (V.S.), the Department of Oncology and Hematology, S. Orsola-Malpighi University Hospital, Bologna (C.F.), the University of Pavia, Fondazione IRCCS Policlinico S. Matteo, Pavia (M.C.), the Hematology Unit, Santi Antonio e Biagio e Cesare Arrigo Hospital, Alessandria (F.S., V.G.), and Dipartimento Biomedicina e Prevenzione, University of Rome Tor Vergata, Rome (M.-T.V.) - all in Italy; the Hematology Department, University Hospital of Salamanca, Institute of Biomedical Research of Salamanca, Salamanca (M.D.-C.), Unidad de Hematología, Hospital Universitario Virgen del Rocío, Seville (J.F.F.), and the Department of Hematology, Hospital Universitario Cruces, Vizcaya (B.A.) - all in Spain; the Department of Hematology Science, School of Medicine, Ankara University, Ankara, Turkey (O.I.); the Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland (M.A.S.); the Department of Hematology, Algemeen Ziekenhuis Sint-Jan, Bruges (D.S.), and Universitair Ziekenhuis Gent, Ghent (D.M.) - both in Belgium; the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore (A.E.D.); the Division of Hematology-Oncology, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center (J.G.J.), and Albert Einstein College of Medicine (A.V.) - both in New York; the Department of Hematology, University Medical Center of Groningen, University of Groningen, Groningen, the Netherlands (E.V.); Stanford University Cancer Center, Stanford, CA (P.L.G.); the Center for Hematology and Regenerative Medicine, Department of Medicine, Karolinska Institutet, Stockholm (E.H.-L.); the Department of Internal Medicine, Yale School of Medicine, Yale University, New Haven, CT (A.M.Z.); Vanderbilt University School of Medicine, Vanderbilt-Ingram Cancer Center, Nashville (M.R.S.); Celgene, Summit, NJ (A.L., J.Z., A.R., D.R.D.); Celgene International, Boudry, Switzerland (A.B.); Acceleron Pharma, Cambridge, MA (P.G.L., M.L.S.); and Moffitt Cancer Center, Tampa, FL (R.S.K., A.F.L.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1908892DOI Listing
January 2020

Prognostic impact of peripheral blood WT1-mRNA expression in patients with MDS.

Blood Cancer J 2019 11 12;9(11):86. Epub 2019 Nov 12.

Department of Hematology, Oncology and Clinical Immunology, University of Duesseldorf, Medical Faculty, Duesseldorf, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-019-0248-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6851368PMC
November 2019

EASIX for prediction of survival in lower-risk myelodysplastic syndromes.

Blood Cancer J 2019 11 11;9(11):85. Epub 2019 Nov 11.

Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-019-0247-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6848148PMC
November 2019

Neut-X can be successfully used as diagnostic and prognostic tool in MDS.

Leuk Res 2019 11 13;86:106224. Epub 2019 Sep 13.

Universitätsklinikum Düsseldorf, Heinrich-Heine-University, Moorenstr. 5, Düsseldorf, 40225, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2019.106224DOI Listing
November 2019

Daratumumab for treatment of pure red cell aplasia after allogeneic stem cell transplantation.

Bone Marrow Transplant 2020 Jun 3;55(6):1191-1193. Epub 2019 Sep 3.

Department of Hematology, Oncology and Clinical Immunology, University Hospital Duesseldorf, Medical Faculty, Duesseldorf, Germany.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41409-019-0664-4
Publisher Site
http://dx.doi.org/10.1038/s41409-019-0664-4DOI Listing
June 2020

Novel therapies in low- and high-risk myelodysplastic syndrome.

Expert Rev Hematol 2019 10 31;12(10):893-908. Epub 2019 Jul 31.

Department of Hematology, Oncology and Clinical Immunology, University Hospital Düsseldorf , Düsseldorf , Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2019.1647778DOI Listing
October 2019

Molecular genetics in allogeneic blood stem cell transplantation for myelodysplastic syndromes.

Expert Rev Hematol 2019 10 25;12(10):821-831. Epub 2019 Jul 25.

Departments of Hematology, Oncology and Clinical Immunology, Heinrich Heine University, Medical Faculty, University Hospital Düsseldorf , Düsseldorf , Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2019.1645004DOI Listing
October 2019

Spontaneous remission in a patient with very late relapse of acute myeloid leukemia 17 years after allogeneic blood stem cell transplantation.

Eur J Haematol 2019 Aug 17;103(2):131-133. Epub 2019 Jun 17.

Department of Hematology, Oncology and Clinical Immunology, Medical Faculty, University of Duesseldorf, Duesseldorf, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.13245DOI Listing
August 2019

Comprehensive geriatric assessment predicts azacitidine treatment duration and survival in older patients with myelodysplastic syndromes.

J Geriatr Oncol 2020 01 22;11(1):114-120. Epub 2019 Apr 22.

School of Medicine, University of Adelaide, Adelaide, Australia; Haematology Department, Royal Adelaide Hospital, Adelaide, Australia; Cancer Research, Cancer Theme, South Australian Health and Medical Research Institute, Adelaide, Australia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jgo.2019.02.002DOI Listing
January 2020

Relapse patterns and treatment strategies in patients receiving allogeneic hematopoietic stem cell transplantation for myeloid malignancies.

Ann Hematol 2019 May 29;98(5):1225-1235. Epub 2019 Mar 29.

Department of Hematology, Oncology and Clinical Immunology, Medical Faculty, University of Duesseldorf, Moorenstr. 5, 40225, Düsseldorf, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03670-6DOI Listing
May 2019

Comparison between Upfront Transplantation and different Pretransplant Cytoreductive Treatment Approaches in Patients with High-Risk Myelodysplastic Syndrome and Secondary Acute Myelogenous Leukemia.

Biol Blood Marrow Transplant 2019 08 15;25(8):1550-1559. Epub 2019 Mar 15.

Department of Hematology, Oncology and Clinical Immunology, University of Duesseldorf, Medical Faculty, Duesseldorf, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.03.011DOI Listing
August 2019

Relapse of Acute Myeloid Leukemia after Allogeneic Stem Cell Transplantation: Prevention, Detection, and Treatment.

Int J Mol Sci 2019 Jan 8;20(1). Epub 2019 Jan 8.

Department of Hematology, Oncology and Clinical Immunology, University of Duesseldorf, Medical Faculty, 40225 Duesseldorf, Germany.

View Article

Download full-text PDF

Source
http://www.mdpi.com/1422-0067/20/1/228
Publisher Site
http://dx.doi.org/10.3390/ijms20010228DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6337734PMC
January 2019

Additional prognostic impact of the percentage of erythroid cells in the bone marrow of patients with myelodysplastic syndromes.

Leuk Res 2019 02 28;77:8-13. Epub 2018 Dec 28.

University of Rochester Medical Center, Department of Pathology, Hematopathology Unit and James P. Wilmot Cancer Institute, Rochester, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2018.12.012DOI Listing
February 2019

Interaction of increasing ICU survival and admittance policies in patients with hematologic neoplasms: A single center experience with 304 patients.

Eur J Haematol 2019 Mar 17;102(3):265-274. Epub 2019 Jan 17.

Department of Haematology, Oncology and Clinical Immunology, Medical Faculty, University Hospital Duesseldorf, Duesseldorf, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.13206DOI Listing
March 2019

Long-term outcome of high risk patients with myelodysplastic syndromes or secondary acute myeloid leukemia receiving intensive chemotherapy.

Ann Hematol 2018 Dec 4;97(12):2325-2332. Epub 2018 Aug 4.

Department of Hematology, Oncology and Clinical Immunology, University Hospital, Heinrich Heine-University, Moorenstr. 5, 40225, Düsseldorf, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-018-3466-7DOI Listing
December 2018

Diagnostic algorithm for lower-risk myelodysplastic syndromes.

Leukemia 2018 08 26;32(8):1679-1696. Epub 2018 Jun 26.

Massachusetts General Hospital, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41375-018-0173-2DOI Listing
August 2018

The current and future role of stem cells in myelodysplastic syndrome therapies.

Expert Rev Hematol 2018 05 22;11(5):411-422. Epub 2018 Mar 22.

a Medical Faculty, Department of Hematology, Oncology and Clinical Immunology , Heinrich Heine University, University Hospital Düsseldorf , Düsseldorf , Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2018.1452611DOI Listing
May 2018

Hypomethylating agents for treatment and prevention of relapse after allogeneic blood stem cell transplantation.

Int J Hematol 2018 Feb 15;107(2):138-150. Epub 2017 Nov 15.

Department of Hematology, Oncology and Clinical Immunology, Medical Faculty, University of Duesseldorf, Moorenstr. 5, 40225, Düsseldorf, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12185-017-2364-4DOI Listing
February 2018

Cytogenetic clonal evolution in myelodysplastic syndromes is associated with inferior prognosis.

Cancer 2017 Dec 26;123(23):4608-4616. Epub 2017 Jul 26.

Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine University, Dusseldorf, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.30917DOI Listing
December 2017

A retrospective study evaluating the impact of infectious complications during azacitidine treatment.

Ann Hematol 2017 Jul 4;96(7):1097-1104. Epub 2017 May 4.

Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University, Moorenstraße 5, 40225, Düsseldorf, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-017-3001-2DOI Listing
July 2017

Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents.

J Clin Oncol 2017 May 28;35(14):1591-1597. Epub 2017 Mar 28.

Sophie Park, Centre Hospitalier Universitaire (CHU) Grenoble Alpes, Université Grenoble Alpes, Grenoble; Jean-François Hamel and Sylvain Thépot, CHU d'Angers; Sylvain Thépot, Université d'Angers, Institut National de la Santé et de la Recherche Médicale, Unité 1232, and LabEx IGO, Angers; Andrea Toma, CHU Henri Mondor, Assistance Publique Hôpitaux de Paris (AP-HP), Université Paris-Est Créteil; Rosa Sapena and Pierre Fenaux, CHU Saint Louis, AP-HP, Université Paris X; François Dreyfus, CHU Cochin, AP-HP, Université Paris V, Paris; Charikleia Kelaidi, CHU Avicenne, Avicenne; Odile Beyne-Rauzy, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse; Aspasia Stamatoullas, Centre Henri Becquerel, Rouen; Agnès Guerci-Bresler, CHU Nancy, Nancy; Dominique Bordessoule, CHU Dupuytren, Limoges; Pascale Cony-Makhoul, Centre Hospitalier Annecy Genevois, Epagny Metz-Tessy; Stéphane Cheze, CHU de Caen, Caen; Eric Wattel, Centre Hospitalier Lyon-Sud, Pierre Bénite, Lyon; Christian Rose, Université Catholique de Lille, Lille; Norbert Vey, Institut Paoli-Calmettes Marseille, Marseille, France; Maria Diez Campelo, Hospital Universitario de Salamanca, Salamanca; Teresa Bernal, Hospital Central de Asturias, Oviedo; Fernando Ramos, Hospital de León, León; Marisa Calabuig, Hospital Clínico de Valencia; Guillermo F. Sanz, Hospital Universitario y Politecnico La Fe, Valencia, Spain; Valeria Santini and Alessandro Sanna, Azienda Ospedaliero Universitaria (AOU) Careggi and University of Florence, Florence; Enrico Balleari, Istituto di Ricovero e Cura a Carattere Scientifico AOU San Martino di Genova, Genova; Daniela Gioia, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, Alessandria; Dario Ferrero, Università degli Studi di Torino; Gianluca Gaidano, Amedeo Avogadro University of Eastern Piedmont, Torino; Giovanni Cametti, Ospedale Maggiore di Chieri, Chieri; Fabrizio Pane, Università Federico II, Napoli, Italy; Mikkael A. Sekeres and Jaime Fensterl, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Rami Komrokji, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; David P. Steensma, Dana-Farber Cancer Institute, Boston, MA; Gail J. Roboz, Weill Medical College of Cornell University, New York, NY; Jennifer Kaivers and Ulrich Germing, University of Düsseldorf, Düsseldorf; Katharina Götze and Catharina Müller-Thomas, Universität München, München, Germany; and Ioannis Kotsianidis, Democritus University of Thrace, University Hospital of Alexandroupolis, Alexandroupolis, Greece.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.71.3271DOI Listing
May 2017

New proposals of the WHO working group (2016) for the diagnosis of myelodysplastic syndromes (MDS): Characteristics of refined MDS types.

Leuk Res 2017 06 27;57:78-84. Epub 2017 Feb 27.

Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Düsseldorf, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2017.02.008DOI Listing
June 2017

Mesenchymal stromal cells in myeloid malignancies.

Blood Res 2016 Dec 23;51(4):225-232. Epub 2016 Dec 23.

Department of Hematology, Oncology and Clinical Immunology, University of Duesseldorf, Medical Faculty, Düesseldorf, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5045/br.2016.51.4.225DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5234241PMC
December 2016

Sorafenib and azacitidine as salvage therapy for relapse of FLT3-ITD mutated AML after allo-SCT.

Eur J Haematol 2017 Apr 2;98(4):348-354. Epub 2017 Feb 2.

Department of Hematology, Oncology and Clinical Immunology, Medical Faculty, University of Duesseldorf, Duesseldorf, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.12832DOI Listing
April 2017

Selective expansion of regulatory T cells during lenalidomide treatment of myelodysplastic syndrome with isolated deletion 5q.

Ann Hematol 2016 Oct 10;95(11):1805-10. Epub 2016 Aug 10.

Medizinische Klinik und Poliklinik I, Universitätsklinikum Carl Gustav Carus Dresden, Technische Universität, Fetscherstr, 74, 01307, Dresden, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-016-2775-yDOI Listing
October 2016

Dysplastic erythroid precursors in the myelodysplastic syndromes and the acute myeloid leukemias: Is there biologic significance? (How should blasts be counted?).

Leuk Res 2016 08 12;47:63-9. Epub 2016 May 12.

Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Düsseldorf, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2016.05.006DOI Listing
August 2016

Causes of death in 2877 patients with myelodysplastic syndromes.

Ann Hematol 2016 May 30;95(6):937-44. Epub 2016 Mar 30.

Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Moorenstr. 5, 40225, Düsseldorf, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-016-2649-3DOI Listing
May 2016

Deep serum discoveries: SDF-1α and HSA fragments in myelodysplastic syndromes.

Am J Hematol 2015 Sep 27;90(9):E185-7. Epub 2015 Jul 27.

Department of Clinical Biochemistry and Pathobiochemistry, Leibniz Center for Diabetes Research, Heinrich-Heine-University, 40225, Düsseldorf, Germany.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/ajh.24070
Publisher Site
http://dx.doi.org/10.1002/ajh.24070DOI Listing
September 2015

In patients with myelodysplastic syndromes with del(5q), factors other than age and sex contribute to the prognostic advantage, which diminishes over time.

Br J Haematol 2015 Sep 11;170(5):687-93. Epub 2015 May 11.

Klinik für Hämatologie Onkologie und Klinische Immunologie, Heinrich-Heine-Universität, Düsseldorf, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.13496DOI Listing
September 2015

Change of prognosis of patients with myelodysplastic syndromes during the last 30 years.

Leuk Res 2015 Jul 15;39(7):679-83. Epub 2015 Apr 15.

Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Duesseldorf, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2015.04.001DOI Listing
July 2015

Impaired cytotoxicity associated with defective natural killer cell differentiation in myelodysplastic syndromes.

Haematologica 2015 May 14;100(5):643-52. Epub 2015 Feb 14.

Institute for Transplantation Diagnostics and Cell Therapeutics, Medical Faculty, Heinrich-Heine University Düsseldorf, Germany

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2014.118679DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4420213PMC
May 2015

Cellularity, characteristics of hematopoietic parameters and prognosis in myelodysplastic syndromes.

Eur J Haematol 2015 Sep 15;95(3):181-9. Epub 2015 May 15.

Department of Hematology, Oncology, and Clinical Immunology, University Hospital Düsseldorf, Düsseldorf, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.12512DOI Listing
September 2015